Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
about
Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review.Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysis.Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data.Focal lung infiltrate complicating PD-1 inhibitor use: A new pattern of drug-associated lung toxicity?Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis.Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy?Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.Analysis of B7-H4 expression in metastatic pleural adenocarcinoma and therapeutic potential of its antagonists.Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis.PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis.Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review.Rapid and partial remission of primary lesion but complicated by secondary fibrosis after treatment with nivolumab in a lung squamous carcinoma.Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma: A Case Report.Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma
P2860
Q30235360-B6023ECA-DB60-4EC2-86FB-E6A38B773B07Q30249619-77D95C01-2638-4297-A527-49F842A10D5EQ31171172-EE98AA73-ADC2-4478-A19F-A04EEEE1ACA5Q37262696-BCC57D54-A639-4E30-9D95-A502441C5D76Q37306007-1F3ECD34-055F-4D10-BE25-306B62B497C4Q39045550-019ED9DF-5CF4-4FEF-A99B-77660C4C46AEQ39947131-B3A856EC-0639-4905-9E5C-97AC652730E5Q41704716-C6D895D7-FCBE-4EFA-8830-451E8B602782Q42283210-B1FE9268-5829-459B-BBF8-C23F60C4A48DQ46364428-5DFB8E88-0307-4092-98DB-C13062AD55E2Q46694815-25285EA7-E189-4F6B-BF25-94F5378C9BABQ48029549-07A52877-0CD3-4CA2-AC62-92D9FBBFDB16Q50055764-DDD2C9C6-11D9-4DF7-9A54-72F3EB2BCC70Q52655558-257CE9EB-C476-4457-85F9-821B3CB2FFECQ58797003-28853003-760C-429A-9ED4-B9F271C24803
P2860
Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Risk of elevated transaminases ...... t inhibitors: a meta-analysis.
@en
type
label
Risk of elevated transaminases ...... t inhibitors: a meta-analysis.
@en
prefLabel
Risk of elevated transaminases ...... t inhibitors: a meta-analysis.
@en
P2860
P1476
Risk of elevated transaminases ...... nt inhibitors: a meta-analysis
@en
P2093
Mona Fouad
P2860
P304
P356
10.1517/14740338.2015.1085969
P407
P577
2015-09-07T00:00:00Z